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Abstract We have carried out a fatty acid and carbohydrate 
compositional analysis of the protease-resistant core of paired 
helical filaments (prcPHF) isolated from six Alzheimer's diseased 
brains. Fatty acids, long-chain bases and monosaccharides were 
characterized by gas chromatography/mass pectrometry (GC/ 
MS) of fatty acid methyl esters, trimethylsilylated long-chain 
bases, peraeetylated alditol acetates and trimethylsilyl methyl 
glycosides. Glucose and mannose were found to be the only carbo- 
hydrate components. Four of the six prcPHF samples contained 
only glucose while the remaining two samples contained between 
30--40% mannose in addition to glucose. None of the samples were 
found to contain either hydroxylated fatty acids or long-chain 
bases. The average fatty acid profile of prcPHF was highest in 
stearic (C18:0) and palmitic acids (C16:0) with less than 10% 
unsaturated fatty acids. By comparing the carbohydrate and lipid 
composition of prcPHF to similar data for other brain glycolipids, 
it was determined that prcPHF is a unique glycolipid, distinct 
from cerebrosides, gangliosides or brain phospbolipids. The fatty 
acid and carbohydrate composition of a glycolipid isolated from 
a population of normal brains according to the prcPHF protocol 
was found be identical to that of prcPHF glycolipid. It is possible 
that subtle differences in structure or indigenous factors are re- 
sponsible for the initiation of PHF formation in vivo. 
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1. Introduction 
Neurofibrillary tangles (NFT) and senile plaques (SP) can be 
found in the hippocampus of normal aged individuals, but 
occur with much greater density in the hippocampus and tem- 
poral cortex of patients uffering from Alzheimer's disease 
(AD) and Down syndrome individuals greater than 45 years of 
age [1-3]. The presence of NFT and SP in histological sections 
serves as a basis of diagnosis for AD and the density of tangles 
has been correlated with the severity of dementia [4,5]. The 
NFT occur in the perinuclear cell cytoplasm and are composed 
primarily of bundles of paired helical filaments (PHF) [6-11]. 
Since PHF are a common element o both lesions and are 
diagnostic of AD, it is reasonable to assume that an under- 
standing of their composition might lead to a better under- 
standing of the etiology of AD. 
PHF isolated from AD brain NFT remain insoluble under 
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even the most stringent conditions used to solubilize protein 
[12]. For these reasons, they are difficult to characterize using 
standard biochemical techniques. It has been shown that the 
outer, protease-sensitive, fuzzy coat of PHF is composed of a 
hyperphosphorylated form of the microtubule-associated tau 
protein [13 17]. Using scanning transmission electron micros- 
copy it has been estimated that tau outer coat comprises only 
17% of the PHF structure, and the composition of the remain- 
ing 83% that represents the protease resistant core remains 
unknown [17]. 
We have shown by total amino acid analysis that the pro- 
tease-resistant PHF core (prcPHF) structure contains less than 
5 percent protein [18]. X-ray microprobe analysis of these intact 
prcPHF confirmed that they were nonproteinaceous in compo- 
sition [19]. An independent laboratory has previously shown 
that neurofibrillary tangles could be immunolabeled in situ with 
a monoclonal ntibody to a ganglioside [20]. They have since 
shown by immunoelectron microscopy that this antibody will 
immunolabel isolated, intact PHF [21]. The high-resolution ~H 
NMR spectrum of prcPHF in d6-DMSO:D20 (9:1) contains 
resonances which can only be attributed to either fatty acid or 
sugar protons [18]. No resonances are present which can be 
ascribed to a sphingosine long-chain base or to a glycerol back- 
bone, suggesting the absence of phospholipid, ganglioside or 
cerebroside. 
The goal of the present study was to characterize the fatty 
acid and carbohydrate components of prcPHF isolated from 
a population of AD individuals. Common compositional ele- 
ments of the prcPHF samples are then compared to those of 
similarly isolated glycolipid from normal individuals in order 
to deduce features which might be responsible for filament 
formation. 
2. Materials and methods 
2.1. Purification of prcPHF 
Frozen, AD tissue for PHF isolations was obtained from Dr. Wallace 
Tourtellotte of the National Neurological Research Specimen Bank 
(Los Angeles, CA). Tissue from normal aged individuals used for con- 
trol preparations was a gift from Dr. John Richardson, Montreal Gen- 
eral Hospital (Montreal, Quebec, Canada). All samples were provided 
with a clinical history and a report of the neuropathological examina- 
tion. The clinical diagnosis of AD was made based on the criteria 
described by Khachaturian [5]. The AD and contol brains used in this 
study were randomly selected. AD brains with moderate to severe 
numbers of senile plaques and neurofibrillary tangles were used for this 
study, while control brains contained no neurofibrillary pathological 
involvement. Reagents used in prcPHF and control preparations were 
obtained from Sigma Chemical Co. (St. Louis, MO). 
The prcPHF were isolated from gray matter ich in NFT using a 
modification of SDS extraction method that included incubating the 
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PHF with protease to remove protein contaminants and with DNase 
to remove any contaminating DNA. This procedure has previously 
been described in detail elsewhere [18,19,22]. A control fraction was 
isolated using identical brain regions from the non-AD brains by the 
same method used to isolate the prcPHF. The quantity of each prcPHF 
and control fraction was visually assessed by examining each prepara- 
tion by electron microscopy [22]. Each preparation was further moni- 
tored for compositional consistency by high-resolution NMR to insure 
that their spectrum was identical to those previously published [18]. 
2.2. Preparation of trimethylsilyl ethers of methyl glycosides and long- 
chain bases 
A general procedure for the preparation of trimethylsilyl ethers of 
methyl glycosides and long-chain bases has been described [23-26]. 
Accordingly, 500/11 of 0.6 N anhydrous methanolic HC1 was added to 
a freeze dried PHF sample aliquot (300/11 out of 1 ml total volume) or 
to 2 mg sugar standard. The samples were then heated at 75°C over- 
night in sealed tubes. The methanolic HC1 was evaporated at about 
40°C under a stream of argon. An N-acetylation reaction was per- 
formed by adding 200/tl of dry methanol, 20/11 of pyridine and 20/.tl 
of acetic anhydride. The tubes were sealed again and allowed to stand 
at room temperature for at least 6 h. After this period, the reaction 
mixture was evaporated to dryness under a stream of argon. 200 pl of 
SiI-A reagent (Sigma) was added and the sealed tubes heated at 80°C 
for 20 min. The reaction mixture was cooled, centrifuged and the 
supernatant transferred to a sealed clean vial. The sample, dissolved in 
100/.tl of dichloromethane, was then ready for GC injection. 
2.3. GCIMS analysis of fatty acid methyl esters, trimethylsilyl ethers of 
methyl glycosides and long-chain bases 
To a freeze dried PHF sample aliquot (300pl aliquot out of 1 ml total 
volume) 300/11 of 10% HCI in methanol was added in a sealed tube. 
The mixture was heated at 80°C for 2 h. The reaction mixture was 
cooled to room temperature and then successively extracted with two 
200 ~1 portions of hexane. The organic phase was transferred to a clean 
vial, the solvent evaporated under argon, and the sample dissolved in 
100/A dichloromethane. The sample was then ready for GC injection 
[24,27]. 
The assay for fatty acid methyl esters and trimethylsilyl ether deriv- 
atives of methyl glycosides and long-chain bases was carried out on a 
HP-5390 Gas Chromatograph equipped with a flame ionization detec- 
tor (FID), and a Nukol (Supelco) 30 m, 0.32 mm i.d. capillary column 
Table 1 
Fractions of long-chain fatty acids in prcPHF and control glycolipi& 
[24,27,28]. 3/al of each sample was injected in the splitless mode while 
the same volume of each standard was injected in the split mode. 
Nitrogen (zero grade) was used as the carrier at a flow fixed by using 
15 psi of pressure on the carrier gas with a split ratio of 1 : 85. The oven 
temperature was held constant at 100°C for 3 min, then increased at 
10°C per min to a final temperature of 195°C. Injector and detector 
temperatures were 250°C. In most cases amples could be identified by 
comparison of their retention times to those of known standards. 
A Shimadzu QP-1100 EX instrument was also used under identical 
conditions as above when mass detection (MSD) was needed. Saturated 
fatty acid methyl esters were identified on the basis of their McLaferty 
rearrangement product at mass 74 [29]. The remaining fragment ions 
present in the spectrum were used to characterize the parent hydrocar- 
bon. Hydroxyl groups present along the hydrocarbon chain of the fatty 
acid will cause a change in the fragmentation pattern when compared 
with the non-hydroxylated form [27]. The base peak indicates the posi- 
tion of the hydroxyl group, since its mass corresponds to the fragment 
generated by cleavage of the hydrocarbon chain on either side of the 
hydroxyl group. For ct-hydroxylated fatty acids, the base peak is the 
molecular ion [28]. 
2.4. GC/MS analysis ofalditol acetates 
The monosaccharide composition of prcPHF and control glycolipid 
samples was determined by GC/MS of alditol acetate derivatives [25]. 
Accordingly, a PHF or control sample aliquot (300/.tl out of 1 ml total 
volume) was freeze dried and then hydrolyzed by resuspending in 2 M 
triftuoroacetic acid in a sealed tube at 75°C for 2 h. The acid was 
evaporated under a flow of argon and residual acetic acid was elimi- 
nated by addition of isopropanol, followed by blowing to dryness with 
argon (2 × 250 ~1). The hydrolyzate was dissolved in 200 ~1 of 1 M 
ammonium hydroxide containing 10 mg/ml of sodium borodeuteride 
and kept at room temperature for at least 1 h. The reduction was 
stopped by the dropwise addition of glacial acetic acid. When bubbling 
ceased, 0.5 ml of methanol was added and the resulting mixture evap- 
orated under a stream of argon. The addition of methanol was repeated 
three times and the sample vaporated to complete dryness each time. 
The dry residue was redissolved in 0.1 ml of acetic anhydride and 0.1 
ml of dry pyridine. The tube was sealed, vortexed and heated to 120°C 
for 20 min. The acetylation was stopped by drying under a stream of 
argon and the residue dissolved in 0.5 ml of dichloromethane. 0.5 ml 
of water was added and the organic phase transferred to a clean tube 
containing a small amount of anhydrous odium sulfate. The dry or- 
Saturated fats 
Unsaturated fats 
Age/sex/severity C 14 C 16 C 18 
C20 : 1 C22 : 1 C24: 1 Sat 
C20 C22 C24 C16:1 C18:1 
AD1590 83/F/S 3.4 18.3 31.0 11.2 
AD1528 86/M/M 0.0 20.7 57.4 2.6 
AD 1519 891F/M 7.6 39.6 17.6 22.2 
AD 1499 70/F/S 2.9 45.6 29.1 12.2 
AD1937 841M/M 12.0 16.1 67.1 6.0 
AD 1678 871F/S 11.6 41.1 10.1 9.9 
prcPHF samples 
2.4 0.8 4.2 17.5 19. 
0.0 0.0 0.0 11.4 4 
0.0 0.0 0.0 3.6 9. 
0.0 0.0 0.0 2.9 7. 
1.2 0.4 0.0 4.0 4. 
3.2 0.6 0.0 5.4 12. 
Average±S.D. 12.0±14.7 27.0±13.7 32.1±20.5 10.7±5.6 1.0±1.2 0.3±0.3 3.8±7.7 6.4±5.6 6. 3. 
Control samples 
CT714 44/M 8.1 21.7 32.3 10.6 1.1 0.0 1.5 
CT92119 70/M 21.3 18.6 52.7 7.4 0.0 0.0 0.0 
CT9205 75/F 5.7 34.1 18.7 0.3 0.0 0.0 13.3 
CT661 26lF 9.2 25.3 39.6 11.5 0.0 0.0 0.0 
CT1226 57/M 3.6 15.0 44.0 17.0 0.0 0.0 0.7 
CT738 25/M 5.9 23.2 32.5 7.7 0.0 0.0 1.5 
CT1374 15.8 45.6 11.9 8.3 0.3 0.0 6.4 
CT1269 4.2 34.9 44.9 7.1 0.0 0.0 2.0 
Average + S.D. 9.2 + 5.8 27.3 + 9.5 34.6 + 12.9 8.7 + 4.4 0.2+0.4 0.0+0.0 3.2+4.3 
14.3 
0.0 
27.4 
9.9 
10.0 
17.7 
4.9 
4.1 
11.0+8.2 
10. 
0. 
0. 
4. 
9. 
11. 
6. 
2. 
5. 
~As determined by Gc/MS of fatty acid methyl esters. Values are expressed as percent of total fatty acid. 
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ganic solution was transferred toa vial, evaporated and reconstituted 
in 100/21 of dichloromethane. 
GC analysis of alditol acetates was carried out in a fashion similar 
to the GC analysis of fatty acid methyl esters except hat the oven 
temperature was held constant at 170°C for 5 min, then increased at 
a rate of 10°C per min to a final temperature of 195°C. Alditol acetates 
were identified by the presence of mass fragments at 43 (base peak), 115, 
103, 128, 145 and 187. GC/MS identification of trimethylsilyl deriva- 
tives of long-chain base standards was carried out as described [23]. 
3. Results 
3.1. GCIMS characterization of fatty acid methyl esters 
Fatty acids were characterized as their methyl ester deriva- 
tives by GC/MS analysis. Table 1 summarizes the results for 
prcPHF isolated from six AD brains and for control samples 
isolated from six normal brains according to the prcPHF isola- 
tion protocol. Hydroxylated and branched-chain fats were not 
detected. There was no recognizable correlation between the 
age/sex of the patient or severity of AD and the fatty acid 
composition of the isolated prcPHF. The fatty acids character- 
istic of prcPHF do not differ significantly from those of the 
controls. 
The average fatty acid profile for the prcPHF samples is 
shown graphically in Fig. 1, where it is compared to the profile 
for fatty acids in the phospholipid components of whole brain 
grey and white matter [29]. Phospholipids make up approxi- 
mately 60% of the fatty acids in brain tissue and like the 
prcPHF, they contain very little hydroxylated fatty acids. Gan- 
gliosides and cerebrosides, which contain most of the remaining 
fat, have between 30% and 50% of their fatty acid s-hydroxyl- 
ated [31-35]. Of the non-hydroxylated fats, gangliosides con- 
tain approximately 90% stearic acid (C 18:0) while cerebrosides 
contain about 40% C24:0 and C24:1 fatty acids. In contrast, 
the prcPHF and control glycolipids contain only about 30% 
stearic acid and only trace amounts of C24: 0 or C24: 1. As 
shown in Fig. 1, the quantities of fatty acid components also 
differ from fats characteristic of phospholipids. While 
phospholipids contain similar amounts of C 16: 0 and C 18 : 0 as 
prcPHF, they contain substantially more C18:1 and substan- 
tially less C14:0 and C20:0 fats. 
3.2. Carbohydrate and long chain base composition 
Carbohydrate composition was determined by GC/MS anal- 
ysis of alditol acetate derivatives formed from monosaccharides 
released from the acid hydrolysis of prcPHF or control glycol- 
ipid. Since sialic acid is degraded using this procedure [25], the 
carbohydrate composition was verified on our samples by GC/ 
MS analysis of the trimethylsilyl derivatives of methyl glyco- 
sides. A similar derivatization procedure may also be used for 
the determination of long-chain bases, such as sphingosine, 
dihydrosphingosine and phytosphingosine [23]. Glucose and 
mannose were the only sugars detected in either the prcPHF 
or the control glycolipid samples (Table 2). Glucose occurred 
as the major component inall of the samples (an average of 85% 
of the total for the prcPHF and 96% of the total for the control) 
and in the majority of samples, it was the only monosaccharide 
detected. Three of the six control glycolipid samples contained 
between 5-12% mannose. The mannose fraction was signifi- 
cantly higher in two of the six prcPHF samples, comprising 
30-40% of the total carbohydrate. No long-chain bases or sialic 
acid were detected in any of our samples. This finding is in 
agreement with the absence of proton resonances assignable to 
these species in the NMR of prcPHF [18]. 
4. Discussion 
The GC/MS analysis of the lipid components of prcPHF 
shows the absence of long-chain base or glycerol trimethylsilyl 
derivatives which would be excepted had a cerebroside, gangli- 
oside or phospholipid component been present. Our prelimi- 
nary studies indicate that this result is corroborated by the 
absence of signals arising from these components in the ~H 
NMR of intact or acid hydrolyzed prcPHF [18]. We have been 
unable to find any solvent conditions, including organic sol- 
vents, which are able to selectively extract he fatty acid compo- 
nent of prcPHF from the carbohydrate component. This, along 
with the absence of long-chain base or glycerol moieties, sug- 
gests that the fatty acids are either covalently linked to the 
carbohydrate or form a strongly associated complex with it. 
Heterogeneity in the carbohydrate composition between 
prcPHF isolated from different AD brains is evident from GC/ 
MS analysis of alditol acetates (Table 2). Four of the six 
prcPHF samples were found to contain glucose as their sole 
monosaccharide component. In two of the samples a significant 
fraction of mannose (up to 40%) was present in addition to 
glucose. As many as three independent preparations were done 
from many of these brains and in each case, a repeatable and 
consistent ratio of glucose and mannose was found. Thus, the 
amount of glucose and mannose in each brain fraction appear 
to be characteristic of that particular brain and not the result 
of an experimental variable in a particular preparation. 
The average fatty acid profile of prcPHF glycolipid, as deter- 
mined by GC/MS analysis of fatty acid methyl esters, is unique 
in that it is unlike the fatty acid profile of brain ganglioside, 
Table 2 
Carbohydrate composition of PHF from AD brains and glycolipid isolated from control brains according to PHF isolation procedure" 
AD/PHF Control brain 
Case Age/sex/severity Glucose Mannose Case Age/sex Glucose Mannose 
AD1678 87/F/S 100.0 N.D. CT714 44/M 95.0 5.0 
AD 1590 83/F/S 100.0 N.D. CT92119 70/M 100.0 N.D. 
AD 1528 86/M/M 60.0 40.0 CT9205 75/F 100.0 N.D. 
AD 1519 89/F/M 100.0 N.D. CT661 26/F 92.0 8.0 
AD1499 70/F/S 70.0 30.0 CT1226 57/M 100.0 N.D. 
AD1937 84/M/M 100.0 N.D. CT738 25/M 88.0 12.0 
Average + S.D. 85.7 + 16.8 14.3 + 16.8 95.8 _+ 4.6 4.2 + 4.6 
aAs determined from GC/MS of alditol acetates. N.D. = not detectable. 
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Fig. 1. Average fatty acid composition of six prcPHF samples compared to the average fatty acid compostion of phospholipids inwhole brain grey 
and white matter [30]. 
cerebroside or any of the components of brain phospholipid 
[30~34]. It is highest in the fractions of saturated fats C18:0, 
C16:0 and C20:0, followed by the fractions of unsaturated fats 
C18:1 and C20:1 present. However, like the carbohydrate 
component, here appears to be considerable variation in the 
fraction of any specific fatty acid component between samples 
isolated from different individuals. Taken as a whole, our re- 
sults suggests ignificant structural heterogeneity in both the 
carbohydrate and fatty acid components of prcPHF glycolipid 
may be tolerated, while still satisfying the criteria for filament 
formation. 
Glycolipids similar in composition to prcPHF may be iso- 
lated from the brains of normal individuals. No significant 
differences were found in any of the fatty acids or monosac- 
charide components between prcPHF and glycolipid purified 
from normal brains according to the prcPHF isolation proto- 
col. It has previously been reported that lipid from crude prep- 
arations of AD brains contains a higher degree of unsaturated 
fatty acid compared to lipid similarly isolated from aged- 
matched control brains [35]. In our purified preparations, we 
found that the average ratio of unsaturated to saturated fatty 
acid for the prcPHF did not differ significantly from that of the 
control lipid. Because there may be other factors which are 
abnormal in the neurons of AD individuals, it is difficult to 
solely attribute helical filament formation to the compositional 
characteristics of the prcPHF glycolipid. That more than a 
single structural factor is involved in filament formation is also 
suggested by the structural diversity of prcPHF glycolipid be- 
tween individuals. It is likely that a combination of subtle dif- 
ferences in the structure and concentration of prcPHF glycol- 
ipid along with the abnormal presence of hyperphosphorylated 
tau or metal ion may play a role in the nucleation of filaments. 
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